Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8102952 | 0.99 | ADORA2A (0.33) | ADORA2AADORA1ALDH1A1KMT2AKDM4E | |
| SCHEMBL3028481 | 0.91 | CHRM2 (0.37) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14311499 | 0.91 | CHRM2 (0.37) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3028483 | 0.91 | CHRM2 (0.37) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4373864 | 0.87 | MAPK14 (0.32) | ADORA2AADORA1ALDH1A1KDM4EMAPK14 | |
| SCHEMBL4369476 | 0.87 | SMN1; SMN2 (0.40) | ADORA2AADORA1ALDH1A1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL8643932 | 0.85 | CA1 (0.38) | ALDH1A1 | |
| SCHEMBL4365170 | 0.85 | ALDH1A1 (0.33) | ADORA2AADORA1ALDH1A1KMT2AKDM4E | |
| SCHEMBL14287268 | 0.85 | DRD2 (0.36) | ALDH1A1KMT2AKDM4EMEN1CHRM3 | |
| SCHEMBL4361494 | 0.84 | MAOA (0.38) | ADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-10-30 | — | — | US | claimed |
| EP-1736468-A2 | Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation | NeuroSearch A/S (DK) | 2006-12-27 | — | — | EP | claimed |
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | GROENBORG METTE | 2006-10-12 | — | — | US | claimed |
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2006-04-13 | — | — | US | claimed |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | NEUROSEARCH A/S | 2004-07-22 | — | — | US | claimed |
| JP-2003520851-A | — | — | 2003-07-08 | — | — | JP | claimed |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | ANIONA APS (DK) | 2003-02-27 | — | — | US | claimed |
| EP-1255734-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NeuroSearch A/S (DK) | 2002-11-13 | — | — | EP | claimed |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | AROS PHARMA APS (DK) | 2002-05-16 | — | — | US | claimed |
| EP-1183025-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2002-03-06 | — | — | EP | claimed |
| WO-2001055110-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 2001-08-02 | — | — | WO | claimed |
| WO-2000071102-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2000-11-30 | — | — | WO | claimed |
| US-5780493-A | TREATING BRAIN DISORDERS | NEUROSEARCH A/S (DK) | 1998-07-14 | — | — | US | claimed |
| US-7595336-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2009-09-29 | — | — | US | disclosed |
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7288653-B2 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-10-30 | — | — | US | disclosed |
| EP-1183025-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2001055110-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
| WO-2000071102-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2000-11-30 | — | — | WO | disclosed |
| US-5843945-A | AMPA antagonists and a method of treatment | NEUROSEARCH A/S (DK) | 1998-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | ADORA2A 1299/4885ADORA1 1257/4885ALDH1A1 2854/4885 |
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | ADORA2A 1299/4885ADORA1 1257/4885ALDH1A1 2854/4885 |
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | BDNF, NTRK2, NGF | ADORA2A 252/4885ADORA1 589/4885ALDH1A1 2973/4885 |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | ASIC1, ASIC3, TRPM4 | ADORA2A 740/4885ADORA1 512/4885ALDH1A1 2160/4885 |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | ADORA2A 1299/4885ADORA1 1257/4885ALDH1A1 2854/4885 |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | BDNF, NTRK2, NGF | ADORA2A 252/4885ADORA1 589/4885ALDH1A1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.